Business Description
Y-mAbs Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US9842411095
Description
Financial Strength
7/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 61.07 | |||||
Equity-to-Asset | 0.66 | |||||
Debt-to-Equity | 0.01 | |||||
Debt-to-EBITDA | -0.05 | |||||
Interest Coverage | N/A | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | 3.26 | |||||
Beneish M-Score | -2.19 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 55.5 | |||||
3-Year EBITDA Growth Rate | 42.3 | |||||
3-Year EPS without NRI Growth Rate | 45.2 | |||||
3-Year FCF Growth Rate | 35.1 | |||||
3-Year Book Growth Rate | -3.9 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate | -7.46 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 12.64 |
Momentum Rank
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 39.31 | |||||
9-Day RSI | 43.12 | |||||
14-Day RSI | 46.38 | |||||
6-1 Month Momentum % | -8.06 | |||||
12-1 Month Momentum % | 162.91 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 2.92 | |||||
Quick Ratio | 2.72 | |||||
Cash Ratio | 1.79 | |||||
Days Inventory | 254.41 | |||||
Days Sales Outstanding | 87.07 | |||||
Days Payable | 280.58 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -2.4 | |||||
Shareholder Yield % | 0.05 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 88.63 | |||||
Operating Margin % | -31.94 | |||||
Net Margin % | -28.44 | |||||
FCF Margin % | -14.5 | |||||
ROE % | -24.6 | |||||
ROA % | -18.75 | |||||
ROIC % | -100.33 | |||||
3-Year ROIIC % | 477.14 | |||||
ROC (Joel Greenblatt) % | -284.05 | |||||
ROCE % | -26.12 |
GF Value Rank
7/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 6.64 | |||||
PB Ratio | 6.15 | |||||
Price-to-Tangible-Book | 6.33 | |||||
EV-to-EBIT | -18.19 | |||||
EV-to-EBITDA | -18.62 | |||||
EV-to-Revenue | 5.81 | |||||
EV-to-Forward-Revenue | 4.09 | |||||
EV-to-FCF | -39.88 | |||||
Price-to-Net-Current-Asset-Value | 7.5 | |||||
Price-to-Net-Cash | 20.18 | |||||
Earnings Yield (Greenblatt) % | -5.5 | |||||
FCF Yield % | -2.14 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:YMAB
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Y-mAbs Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil $) | 86.546 | ||
EPS (TTM) ($) | -0.56 | ||
Beta | 0.34 | ||
Volatility % | 94.41 | ||
14-Day RSI | 46.38 | ||
14-Day ATR ($) | 0.798877 | ||
20-Day SMA ($) | 13.535 | ||
12-1 Month Momentum % | 162.91 | ||
52-Week Range ($) | 4.69 - 20.9 | ||
Shares Outstanding (Mil) | 44.57 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 4 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Y-mAbs Therapeutics Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Y-mAbs Therapeutics Inc Stock Events
Event | Date | Price($) | ||
---|---|---|---|---|
No Event Data |
Y-mAbs Therapeutics Inc Frequently Asked Questions
What is Y-mAbs Therapeutics Inc(YMAB)'s stock price today?
When is next earnings date of Y-mAbs Therapeutics Inc(YMAB)?
Does Y-mAbs Therapeutics Inc(YMAB) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |